{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:08:56Z","timestamp":1783973336728,"version":"3.55.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/mjt.0b013e3181960819","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T08:18:26Z","timestamp":1258186706000},"page":"573-578","source":"Crossref","is-referenced-by-count":16,"title":["Peg-Interferon in Acute and Chronic Hepatitis C: A Review"],"prefix":"10.1097","volume":"16","author":[{"given":"Emilio","family":"Palumbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-18-20210202","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C.","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"R2-18-20210202","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"R3-18-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2004.11.021","article-title":"Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.","volume":"42","author":"Santantonio","year":"2005","journal-title":"J Hepatol"},{"key":"R4-18-20210202","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s15010-005-4032-5","article-title":"Peg-interferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.","volume":"33","author":"Scotto","year":"2005","journal-title":"Infection"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peg-interferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R6-18-20210202","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1590-8658(04)80002-1","article-title":"Pharmacokinetics of pegylated interferons: what is misleading?","volume":"36","author":"Caliceti","year":"2004","journal-title":"Dig Liver Dis"},{"issue":"24","key":"R8-18-20210202","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.2174\/1381612023393242","article-title":"Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.","volume":"8","author":"Youngster","year":"2002","journal-title":"Curr Pharm Des"},{"issue":"Suppl 1","key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1002\/hep.1840360702","article-title":"National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/jhep.2001.27831","article-title":"Estimating progression to cirrhosis in chronic hepatitis C virus infection.","volume":"34","author":"Freeman","year":"2001","journal-title":"Hepatology"},{"key":"R11-18-20210202","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7150\/ijms.3.63","article-title":"A practical approach to managing patients with HCV infection.","volume":"3","author":"Huang","year":"2006","journal-title":"Int J Med Sci"},{"key":"R12-18-20210202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-2005-864783","article-title":"Current and future concepts in hepatitis C therapy.","volume":"25","author":"Pawlotsky","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3810\/pgm.2003.07.1452","article-title":"Current therapies for chronic hepatitis C.","volume":"114","author":"Patel","year":"2003","journal-title":"Postgrad Med"},{"key":"R14-18-20210202","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"AASLD practice guideline: diagnosis, management and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"R15-18-20210202","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7150\/ijms.3.69","article-title":"Treatment of chronic HCV infection in special populations.","volume":"3","author":"Hoefs","year":"2006","journal-title":"Int J Med Sci"},{"key":"R16-18-20210202","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1572-0241.2007.01139.x","article-title":"Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.","volume":"102","author":"McHutchison","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R17-18-20210202","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/j.1572-0241.2007.01223.x","article-title":"Hepatitis C seems milder in patients with hemophilia.","volume":"102","author":"Douglas","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R18-18-20210202","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0168-8278(03)00461-6","article-title":"When and how to treat acute hepatitis C.","volume":"39","author":"Licata","year":"2003","journal-title":"J Hepatol"},{"key":"R19-18-20210202","first-page":"264","article-title":"Treatment of acute hepatitis C with interferon alfa-2b prevents chronicity.","volume":"30","author":"Delwaide","year":"1999","journal-title":"Hepatology"},{"key":"R20-18-20210202","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0168-8278(94)80246-7","article-title":"A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.","volume":"21","author":"Hwang","year":"1994","journal-title":"J Hepatol"},{"key":"R21-18-20210202","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1002\/hep.1840360725","article-title":"Therapy of acute hepatitis C.","volume":"36","author":"Alberti","year":"2002","journal-title":"Hepatology"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200911000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T06:46:41Z","timestamp":1739429201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200911000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181960819","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}